<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03069521</url>
  </required_header>
  <id_info>
    <org_study_id>ECL00041</org_study_id>
    <nct_id>NCT03069521</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety of the EndoArt™ for Treatment of Subjects Suffering From Corneal Edema</brief_title>
  <official_title>Prospective, Feasibility Study to Evaluate the Safety of the EndoArt™ for Treatment of Subjects Suffering From Corneal Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eye-yon Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eye-yon Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, feasibility study to evaluate the safety of the EndoArt® for treatment of 30&#xD;
      subjects suffering from corneal edema. Followed up for 12 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title: Prospective, feasibility study to evaluate the safety of the EndoArt® for treatment of&#xD;
      subjects suffering from corneal edema&#xD;
&#xD;
      Device: EndoArt® (Artificial Endothelial Layer)&#xD;
&#xD;
      Intended Use: The EndoArt® device is intended for use as an endothelial kearatoprosthesis in&#xD;
      patients with chronic cornel edema&#xD;
&#xD;
      Study Design: Prospective open-label feasibility clinical study&#xD;
&#xD;
      Study Objectives: To evaluate the safety of the EndoArt® implanted in subjects suffering from&#xD;
      corneal edema.&#xD;
&#xD;
      Study Hypothesis: Treatment with the EndoArt® is safe and may result in alleviating symptoms&#xD;
      resulting from chronic corneal edema (corneal thickness).&#xD;
&#xD;
      Study population: Men and women suffering from a decrease in vision due to chronic corneal&#xD;
      edema that meet the inclusion/exclusion criteria and provide written Informed Consent will&#xD;
      enrolled in the study.&#xD;
&#xD;
      Enrollment: A total of 20 subjects will be enrolled.&#xD;
&#xD;
      Study Duration: Completion of active enrollment is anticipated to last approximately 18&#xD;
      months. The primary end point will be achieved when the final study subject has completed 6&#xD;
      month follow up. Subject will be followed up to 12 month.&#xD;
&#xD;
      Primary Safety Endpoint: The frequency and severity of all treatment-related adverse events,&#xD;
      during and after implantation of the EndoArt® and throughout the 6 month follow-up period.&#xD;
      Adverse events will be assessed on a continuous basis from the procedure through the study&#xD;
      completion at 6 months. Related adverse events include: corneal perforation, melting,&#xD;
      uncontrolled inflammation, severe infection.&#xD;
&#xD;
      Secondary Efficacy Endpoints: Corneal thickness, Subjective corneal clarity, Pain as assessed&#xD;
      by a Visual Analogue Scale (VAS) Measurement Best Corrected Distance Visual Acuity (BCDVA)&#xD;
&#xD;
      Study Treatment: Subjects will be implanted with the EndoArt®&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2017</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related adverse events</measure>
    <time_frame>6 months following EndoArt implantaion</time_frame>
    <description>frequency and severity of all treatment-related adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective corneal clarity</measure>
    <time_frame>12 months following EndoArt implantaion</time_frame>
    <description>corneal clarity will be graded by the investigator.&#xD;
Scoring is as follow:&#xD;
0- clear&#xD;
1-iris details can be seen&#xD;
2- iris details are obscure&#xD;
3- can hardly see the pupil&#xD;
4- pupil or iris details ca not be seen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as assessed by a Visual Analogue Scale (VAS)</measure>
    <time_frame>12 months following EndoArt implantaion</time_frame>
    <description>VAS is a horizontal line, 100 mm in length, anchored by word descriptors at each end.&#xD;
The subject marks on the line the point that he feels represents his perception of his current state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement Best Corrected Distance Visual Acuity (BCDVA)</measure>
    <time_frame>12 months following EndoArt implantaion</time_frame>
    <description>Visual acuity on the distance chart with best manifest correction for that distance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal thickness</measure>
    <time_frame>12 months following EndoArt implantaion</time_frame>
    <description>Corneal thickness will be measured by anterior segment Optical Coherence Tomography (OCT).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Cornel Edema</condition>
  <arm_group>
    <arm_group_label>EndoArt®</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>EndoArt® Artificial Endothelial Layer</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EndoArt® Artificial Endothelial Layer</intervention_name>
    <description>device is intended for use as an endothelial kearatoprosthesis</description>
    <arm_group_label>EndoArt®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is over 40 years old&#xD;
&#xD;
          2. Subject with chronic corneal edema.&#xD;
&#xD;
          3. Subject with corneal thickness &gt;650 µm&#xD;
&#xD;
          4. Subject with visual acuity 6/30 or worse (equivalent ETDRS)&#xD;
&#xD;
          5. Subject with better visual acuity in the contralateral eye.&#xD;
&#xD;
          6. Pseudophakic subject (anterior or posterior) with stable IOL.&#xD;
&#xD;
          7. Subject understands the study requirements and the treatment procedures and provides&#xD;
             written Informed Consent before any study-specific tests or procedures are performed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject with best corrected visual acuity of 6/30 or worse in the fellow eye&#xD;
&#xD;
          2. Subject with history of ocular Herpes keratitis&#xD;
&#xD;
          3. Subject with severely scarred cornea (unfit for regular endothelial keratoplasty)&#xD;
&#xD;
          4. Subject with irregular posterior cornea (e.g. post PKP)&#xD;
&#xD;
          5. Subject who is suffering from infection of the cornea&#xD;
&#xD;
          6. Patients with band keratopathy and/or limbal stem cell deficiency.&#xD;
&#xD;
          7. Subject with clinical moderate to severe dry eye&#xD;
&#xD;
          8. Subject with phthisis or phthisis suspect&#xD;
&#xD;
          9. Subject with low ocular pressure ≤6 mmHg or higher than 25 mmHg.&#xD;
&#xD;
         10. Subject with aphakica&#xD;
&#xD;
         11. Subject with pseudophakodonesis&#xD;
&#xD;
         12. Subject with large iris defect which can compromise intraoperative AC stability.&#xD;
&#xD;
         13. Subjects after corneal refractive surgery.&#xD;
&#xD;
         14. Subject with glaucoma shunt (e.g. Ahmend valve)&#xD;
&#xD;
         15. Subject with neurotrophic corneal history&#xD;
&#xD;
         16. Subject with history of persistent corneal erosion difficulties with epithelial growth&#xD;
             (re-epithelization)&#xD;
&#xD;
         17. Subject who is currently participating or have participated in an investigational&#xD;
             study, other than this study, within the past 60 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Igor Kaiserman, Prof.</last_name>
    <phone>972-86745941</phone>
    <email>ork@bmc.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>International Vision Correction Research Centre (IVCRC) Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerd U. Auffarth, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Raquel Willrich Amroussi, M.A</last_name>
      <email>raquel.willrichamroussi@med.uni-heidelberg.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Rostock</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Barzilai MC</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor Kaiserman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Be'er Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Knyazer Boris, MD</last_name>
      <email>Knyazer@bgu.ac.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Modi Naftali, MD</last_name>
      <email>naftalimo@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assuta Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Israel Leshem, Dr.</last_name>
      <email>israell@assuta.co.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Souraski Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Lapid- Gortzak, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Monique Wezel</last_name>
      <email>m.wezel@amsterdamumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>IMO - Institut de Microcirurgia Ocular</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Barbany, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Laura González</last_name>
      <email>gonzalez@imo.es</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Servicio de Oftalmología, Hospital Universitario Miguel Servet, Zaragoza</name>
      <address>
        <city>Saragossa</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 19, 2017</study_first_submitted>
  <study_first_submitted_qc>February 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <last_update_submitted>October 24, 2021</last_update_submitted>
  <last_update_submitted_qc>October 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Corneal Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

